Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.44 |
| ▸ | USP7 | Q93009 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30725703 | 1.00 | CYP11B2 (0.57) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL17116617 | 0.86 | CYP11B2 (0.62) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL17116594 | 0.85 | CYP11B2 (0.57) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL2983844 | 0.84 | CYP11B2 (0.61) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL382109 | 0.81 | CYP11B2 (0.59) | CYP11B2CYP11B1MAP4K4IRAK4KCNH2 | |
| SCHEMBL969074 | 0.81 | CYP11B2 (0.61) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL17116450 | 0.81 | CYP11B2 (0.61) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL12947990 | 0.81 | CYP11B2 (0.57) | CYP11B2CYP11B1MAP4K4PRMT5WDR77 | |
| SCHEMBL6085958 | 0.81 | CYP11B2 (0.66) | CYP11B2CYP11B1MAP4K4 | |
| SCHEMBL2979806 | 0.81 | CYP11B2 (0.56) | CYP11B2CYP11B1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543232-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2019-09-25 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | CYP11B2 1869/4885CYP11B1 1418/4885MAP4K4 1996/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CYP11B2 9/4885CYP11B1 10/4885MAP4K4 2988/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CYP11B2 9/4885CYP11B1 10/4885MAP4K4 2988/4885 |
| US-20210002269-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP19A1 | CYP11B2 6/4885CYP11B1 5/4885MAP4K4 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.